GlassScriptPhysician profile
George D Sagrera
NPI 1093772402
$3,711.63
in general payments reported to CMS, 2019-2025
28 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $712 · 2021: $621 · 2022: $402 · 2023: $657 · 2024: $251 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.18 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Allergan, INC. | $635.41 | 2019-2020 | |
| Amgen INC. | $289.02 | 2019-2023 | Evenity, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $219.19 | 2019-2021 | |
| Pfizer INC. | $209.58 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.81 | 2020-2022 | |
| Gilead Sciences, INC. | $195.61 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $142.78 | 2022-2023 | Quviviq |
| Lilly USA, LLC | $137.78 | 2020-2025 | Jardiance |
| Corium, LLC | $111.77 | 2022-2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.99 | 2019-2023 | Jardiance |
| Jazz Pharmaceuticals INC. | $100.00 | 2019 | |
| Glaxosmithkline, LLC. | $83.58 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.43 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $64.13 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $43.74 | 2020 | |
| Abbott Laboratories | $40.25 | 2023-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $35.38 | 2022-2024 | Zoryve |
| Novo Nordisk INC | $34.12 | 2020-2023 | Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $31.51 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $29.06 | 2025 | |
| Shire North American Group INC | $27.62 | 2019 | |
| Lundbeck LLC | $26.26 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.09 | 2020 | |
| Sanofi-Aventis U.S. LLC | $18.00 | 2019 | |
| Horizon Therapeutics Plc | $12.73 | 2019 | |
| Supernus Pharmaceuticals, INC. | $12.70 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sagrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.